Uncategorized
LL-37: The Antimicrobial Peptide for Immunity and Tissue Repair Research
LL-37: The Antimicrobial Peptide for Immunity and Tissue Repair Research
LL-37 is the only human cathelicidin antimicrobial peptide, a multifunctional immune molecule with direct antimicrobial activity and broad immunomodulatory, wound-healing, and anti-inflammatory effects. It is a cornerstone of innate immunity research and a rising star in tissue repair and regenerative peptide studies. This guide reviews its mechanism, evidence, applications, dosing, and safety.
1. What Is LL-37?
LL-37 is a 37-amino-acid cationic amphipathic peptide cleaved from the C-terminal region of the human cathelicidin precursor hCAP18. It is expressed by epithelial cells, keratinocytes, and immune cells, and its levels change in infection, inflammation, and skin disorders. Its name reflects its two N-terminal leucines and length (37 residues).
- Peptide type: Human cathelicidin antimicrobial peptide (AMP)
- Precursor: hCAP18 (cathelicidin)
- Expression: Epithelial, immune, and skin cells
- Administration: Topical or subcutaneous injection in research
- Core effects: Antimicrobial, immunomodulatory, wound healing
- Status: Research compound
2. Mechanism of Action
LL-37’s multifunctionality stems from its membrane-active and signaling properties:
- Direct antimicrobial activity: Disrupts microbial membranes of bacteria, fungi, and enveloped viruses
- Immune modulation: Chemotactic for immune cells; modulates cytokine responses
- Wound healing: Promotes keratinocyte migration, proliferation, and re-epithelialization
- Anti-inflammatory duality: Pro-inflammatory at low doses, anti-inflammatory and LPS-neutralizing at others
3. The Research Landscape
| Research area | Reported findings |
|---|---|
| Antimicrobial research | Active against drug-resistant bacteria, including MRSA strains |
| Wound healing | Accelerated re-epithelialization and angiogenesis in skin wound models |
| Skin disorders | Levels altered in psoriasis, rosacea, and atopic dermatitis — research target |
| Biofilm disruption | Inhibits biofilm formation and disrupts established biofilms |
LL-37 bridges innate immunity and tissue repair, making it one of the most studied human antimicrobial peptides.
4. Research Applications
- Innate immunity research: Antimicrobial defense and immune signaling models
- Tissue repair research: Wound, burn, and skin regeneration protocols
- Anti-biofilm research: Chronic infection and medical device colonization studies
- Inflammatory disease research: Skin and mucosal inflammation modulation
For related immune peptides, see our peptides for immune system support guide and the thymosin alpha-1 guide.
5. Dosing and Protocol Notes
- Topical research use: 0.1-0.5% formulations in wound and skin studies
- Injection research doses: 0.5-2 mg daily or intermittent subcutaneous
- Reconstitution: Use bacteriostatic water; see our reconstitution and dosage guide
- Protocol duration: Wound studies commonly run 1-4 weeks; systemic protocols vary
6. Side Effects and Considerations
- Injection site reactions: Local redness or discomfort
- Cytokine effects: Dose-dependent immune modulation requires careful protocol design
- Hemolysis risk: High concentrations can disrupt mammalian cell membranes — dosing matters
- Contraindications: Pregnancy, lactation, and active autoimmune conditions without oversight
7. Frequently Asked Questions
Is LL-37 an antibiotic? It is an antimicrobial peptide, not a conventional antibiotic — it works through membrane disruption and immune modulation, which may reduce resistance development.
Can LL-37 be used for skin? It is studied topically for wound healing and skin conditions; its expression is altered in several dermatological disorders.
Does LL-37 have systemic effects? It modulates immune responses systemically at higher doses, which is why dosing protocols require care.
Related Reading
- Peptides for Immune System Support
- Thymosin Alpha-1 Guide
- Peptides for Skin, Hair and Wound Healing
- BPC-157 Research Guide
Shop Related Research Compounds
Browse our research catalog, including LL-37, Thymosin Alpha-1, and BPC-157, all supplied with batch COAs.
Disclaimer: This article is for educational and research purposes only. LL-37 is a research compound not approved for general human use. Always consult qualified professionals regarding research protocols.
